Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Bayesian Gets A Boost With Guidance, But Technique Still Not For Everyone

This article was originally published in The Gray Sheet

Executive Summary

The complex calculations of Bayesian statistics are not likely to become standard for FDA device submissions anytime soon, but they could help streamline clinical trials in many more instances, CDRH's top statistics official says

You may also be interested in...

Modifying Clinical Studies Midstream Can Be Done, With Caution, FDA Says

Adaptive device clinical trials, where study is designed in anticipation of midstream changes, are the focus on a new FDA draft guidance. Adaptive trials can reduce the duration and cost of a study without undermining its integrity, but the practice should be applied with caution, FDA says.

Replacing Test Subjects With Computer Models Will Take Cooperation

More collaboration between device companies and with FDA will be needed to employ sophisticated "virtual patient" computer models to reduce the number of patients needed in clinical trials, says Medtronic statistician Tarek Haddad.

Adult Data To Support Pediatric Use? FDA Drafts Decision Tree To Assess Potential

FDA's device center issued draft guidance on leveraging existing adult – and some pediatric – clinical data for extrapolation to pediatric uses of devices. It provides a decision tree for device sponsors to help determine if available data is suitable to demonstrate safety and effectiveness in a younger population.

Related Content





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts